🚀 VC round data is live in beta, check it out!
Synektik Valuation Multiples
Discover revenue and EBITDA valuation multiples for Synektik and similar public comparables like CeriBell, SI-BONE, Japan Lifeline, MedicalSystem Technology and more.
Synektik Overview
About Synektik
Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.
Founded
2011
HQ
Employees
N/A
Website
Financials (LTM)
EV
$645M
Synektik Financials
Synektik reported last 12-month revenue of $231M and EBITDA of $58M.
In the same LTM period, Synektik generated $106M in gross profit, $58M in EBITDA, and $40M in net income.
Revenue (LTM)
Synektik P&L
In the most recent fiscal year, Synektik reported revenue of $215M and EBITDA of $53M.
Synektik expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $231M | XXX | $215M | XXX | XXX | XXX |
| Gross Profit | $106M | XXX | $65M | XXX | XXX | XXX |
| Gross Margin | 46% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | $58M | XXX | $53M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $40M | XXX | $37M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Synektik Stock Performance
Synektik has current market cap of $681M, and enterprise value of $645M.
Market Cap Evolution
Synektik's stock price is $79.83.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $645M | $681M | -0.4% | XXX | XXX | XXX | $4.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSynektik Valuation Multiples
Synektik trades at 2.8x EV/Revenue multiple, and 11.1x EV/EBITDA.
EV / Revenue (LTM)
Synektik Financial Valuation Multiples
As of April 2, 2026, Synektik has market cap of $681M and EV of $645M.
Equity research analysts estimate Synektik's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Synektik has a P/E ratio of 16.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $681M | XXX | $681M | XXX | XXX | XXX |
| EV (current) | $645M | XXX | $645M | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | 11.1x | XXX | 12.1x | XXX | XXX | XXX |
| EV/EBIT | 11.9x | XXX | 12.8x | XXX | XXX | XXX |
| EV/Gross Profit | 6.1x | XXX | 9.9x | XXX | XXX | XXX |
| P/E | 16.9x | XXX | 18.2x | XXX | XXX | XXX |
| EV/FCF | 13.6x | XXX | 24.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Synektik Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Synektik Margins & Growth Rates
Synektik's revenue in the last 12 month grew by 4%.
Synektik's rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Synektik's rule of X is 35% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Synektik Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 19% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 35% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 10% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Synektik Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| CeriBell | XXX | XXX | XXX | XXX | XXX | XXX |
| SI-BONE | XXX | XXX | XXX | XXX | XXX | XXX |
| Japan Lifeline | XXX | XXX | XXX | XXX | XXX | XXX |
| MedicalSystem Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| Sunmax Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Synektik M&A Activity
Synektik acquired XXX companies to date.
Last acquisition by Synektik was on XXXXXXXX, XXXXX. Synektik acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Synektik
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSynektik Investment Activity
Synektik invested in XXX companies to date.
Synektik made its latest investment on XXXXXXXX, XXXXX. Synektik invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Synektik
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Synektik
| When was Synektik founded? | Synektik was founded in 2011. |
| Where is Synektik headquartered? | Synektik is headquartered in Poland. |
| Is Synektik publicly listed? | Yes, Synektik is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Synektik? | Synektik trades under SNT ticker. |
| When did Synektik go public? | Synektik went public in 2011. |
| Who are competitors of Synektik? | Synektik main competitors are CeriBell, SI-BONE, Japan Lifeline, MedicalSystem Technology. |
| What is the current market cap of Synektik? | Synektik's current market cap is $681M. |
| What is the current revenue of Synektik? | Synektik's last 12 months revenue is $231M. |
| What is the current revenue growth of Synektik? | Synektik revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Synektik? | Current revenue multiple of Synektik is 2.8x. |
| Is Synektik profitable? | Yes, Synektik is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Synektik? | Synektik's last 12 months EBITDA is $58M. |
| What is Synektik's EBITDA margin? | Synektik's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Synektik? | Current EBITDA multiple of Synektik is 11.1x. |
| What is the current FCF of Synektik? | Synektik's last 12 months FCF is $48M. |
| What is Synektik's FCF margin? | Synektik's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Synektik? | Current FCF multiple of Synektik is 13.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.